CCM
DYN icon

Catalio Capital Management’s Dyne Therapeutics DYN Stock Holding History

Catalio Capital Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.44M Sell
244,929
-38,025
-13% -$707K 1.02% 29
2026
Q1 		$5.13M Sell
282,954
-236,761
-46% -$4.08M 1.07% 27
2025
Q4 		$10.2M Buy
+519,715
New +$9.84M 1.8% 25

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Catalio Capital Management's DYN Position: Q2 2026 in Review

Catalio Capital Management reduced its Dyne Therapeutics (DYN) stake by 13% in Q2 2026, selling an estimated $707K and leaving 244,929 shares worth $5.44M. The position accounts for 1.02% of the portfolio, ranked #29.

Catalio Capital Management first reported a position in DYN in Q4 2025 and has held it in 3 quarters since. The position peaked at $10.2M in Q4 2025. 246 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Catalio Capital Management held 244,929 shares of Dyne Therapeutics worth $5.44M as of Q2 2026.
  • Catalio Capital Management sold 38,025 Dyne Therapeutics shares in Q2 2026, an estimated $707K.
  • Dyne Therapeutics made up 1.02% of Catalio Capital Management's portfolio in Q2 2026, its #29 holding.
  • Catalio Capital Management first reported a position in Dyne Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Catalio Capital Management's Dyne Therapeutics position peaked at $10.2M in Q4 2025.
  • 246 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Catalio Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.